AgingResearch.NewsJoin free

Calluna Pharma

CompanyNorway

Calluna Pharma develops one asset, in phase 2 (CAL101 in idiopathic pulmonary fibrosis). Mostly antibody acting on S100A4; based in Norway.

1
Asset
Furthest stage
Phase 2
0
Trials
1
Signal

Pipeline

1

  • CAL101

    Blocks S100A4 to inhibit profibrotic signaling and tissue fibrosis.

    Phase 2, Antibody, S100A4, idiopathic pulmonary fibrosis

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Signals1
  • Similar companies6

Intelligence